anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Myofascial trigger points (MTrPs) are a common source of (regional) pain in patients presenting with musculoskeletal pain. Mechanical vibration has been suggested as a treatment for pain relief. In this study, the effects of vibration therapy on people with non-specific neck pain and MTrPs were investigated. Seventeen chronic non-specific neck pain patients were randomly assigned to a treatment (vibration group, n = 9) or control group (n = 8). Vibration group received 10 self-administered sessions of vibration therapy (45-50 Hz for 15 minutes with the subject laying in supine). Perceived neck pain and disability and pressure pain thresholds over MTrPs of the upper trapezius and levator scapulae bilateraly were measured at baseline and after the first, five and 10 treatment sessions.
Bubbling tablets are claimed contg. a salt that forms bubbles, and inulin.  The tablets are used in a soft drink, a nutrient supplement, a dietetic foodstuff, or a ballast material (roughage) prepn. for therapeutic purposes (esp. as a drug), (claimed), to increase the amt. of ballast material in the diet.
All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
The invention provides a caragana fabr. plant bark extract which is prepared by taking caragana fabr. plant bark as a raw material and performing extraction, and the extract comprises, by weight percentage, 1.91-2.42% of beta-sitosterol. Pharmacological experiments prove that the extract is remarkable in antifungal effect and has potential clinical use value. The invention further provides a method for adopting a supercritical CO2 extraction method to extract the caragana fabr. plant bark, and the problems that a conventional organic solvent extraction method is long in time consumption and a poisonous solvent needs to be used are solved.
A method for creating a stratigraphic model is provided. A core is obtained from a wellbore and a detailed graphic core description is created. Wireline data, including a borehole image, is obtained for a cored interval corresponding to the core and processed into an interpretable borehole image. The core description is compared with the interpretable borehole image to create a catalogue of geologic image facies. The borehole image from the entire interval of interest is compared to the catalogue to create a preliminary pseudocore description. The interpretable borehole image is interactively examined and compared with the preliminary pseudocore description to create a master pseudocore interpretation. A second master pseudocore is developed for a second wellbore. A stratigraphic model, and subsequently a reservoir model, may then be created by correlataing between the master pseudocores of the first and second wellbores.
Inspiratory muscle training will be applied simultaneously with aerobic exercise. This program will create the functional IMT. The exercise program will start with a 5-10 minute warm-up and cool down. Aerobic exercise is planned at 60-85% of MHR on the bike for 30-40 minutes, progress will be achieved. Participants will first work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP. After 10 consecutive breathing cycles, participants will be asked to perform 3-4 breath checks. Resistive exercise program, covering all major muscle groups; The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body muscles, abdominal muscles and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1RM.
Compositions of non-racemic mixtures of d- and l-methadone and a method of treating pain using the composition. The composition is especially useful for treating pain of mixed origin. For predominantly neuropathic pain, a mixture of predominantly d-methadone, up to about 90%, is used. For predominantly somatic pain, a mixture of predominantly l-methadone, up to about 90%, is used. The non-racemic mixture of d- and l-methadone may be further combined with a pharmacologically effective amount of a nonopioid component. In another aspect of the invention, the methadone can be combined with an opioid antagonist such as naloxone, naltrexone, or the like.
The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-R) and its related congeners such as pros-linked ribotide and riboside. The invention is based on the discovery that IAA-RP and to a lesser extent IAA-P bind with a high affinity to imidazoline receptors. Antibodies to IAA-RP, IAA-R are additionally provided, as well as screening methods for identification of compounds that either promote or antagonize the activity of IAA-RP, IAA-R and its related congeners. The invention further relates to diagnostic and prognostic methods for detection of abnormalities in levels or activity of IAA-RP and IAA-R. The invention encompasses treatment of disorders related to the imidazoline system, including hypertension, glaucoma, psychiatric (e.g., depression), neurological (e.g., motor disorders, neurodegenerative disorders), diabetes and disorders related to platelet aggregation.
BACKGROUND: Stress urinary incontinence in men is predominantly iatrogenic after radical prostatectomy or transurethral interventions. Current studies show that there is a deficit in the availability of surgical therapy not only in Germany. The aim of this study is to investigate in more detail the structural health care situation of surgical treatment of male stress incontinence in Germany.
MATERIALS AND METHODS: The evaluation of the surgical therapy of male stress incontinence in Germany is based on the OPS (Operationen- und Prozedurenschlüssel-German procedural classification) codes from hospital quality reports from 2011-2019.
RESULTS: From 2012-2019, the number of male incontinence surgeries declined from 2191 to 1445. The number of departments performing incontinence surgeries decreased from 275 to 244. In the multivariate analysis, a high number (≥ 50) of radical prostatectomies/year (RPE/year) is an independent predictor of a high-volume centre (≥ 10 procedures/year; odds ratio [OR] 6.4 [2.3-17.6]; p < 0.001). The most significant decrease was in sling surgery (from 1091 to 410; p < 0.001). Here, the number of cases decreased especially in departments that implanted a high number of slings (≥ 10 slings/year; -69%; -62.4 ± 15.5 surgeries/year; p = 0.007). In addition, the number of departments implanting slings decreased over the investigated time period (from 34 to 10; p < 0.001). This particularly affected departments that also had a low number of RPE/year (from 9 to 0; -100%).
CONCLUSION: The situation of surgical treatment of male stress urinary incontinence in Germany shows a clear decline in sling implantation, especially in small departments. On the one hand, this reflects the increasingly differentiated indications for sling implantation. On the other hand, it raises the suspicion that a gap in care has developed, as the decline was not compensated for by other surgical therapies.
1. A β-lactam antibiotic-containing tablet which comprises 60 to 85% by weight of a β-lactam antibiotic, 1 to 10% by weight of low-substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator and 0.5 to 2% by weight of a binder per tablet. 2. A tablet as claimed in claim 1, wherein the binder is polyvinylpyrrolidone, hydroxypropylcellulose or hydroxypropylmethylcellulose.  3. A tablet as claimed in claim 1 or 2 which further comprises 0.5 to 15% by weight of a synthetic sweetener and/or a granulated synthetic sweetener.  4. A tablet as claimed in claim 3, wherein the synthetic sweetener or the granulated synthetic sweetener has a mean particle size of not less than 150 μm. 5. A tablet as claimed in claim 4, wherein the synthetic sweetener or the granulated synthetic sweetener is not less than 150 μm in particle size. 6. A tablet as claimed in claim 3, wherein the granulated synthetic sweetener comprises a synthetic sweetener, and light anhydrous silicic acid and/or hydrated silicon dioxide. 7. A tablet as claimed in any of claims 1 to 6, wherein the β-lactam antibiotic is cefixime or cefdinir. 8. A tablet as claimed in claim 7 which contains 400-mg potency of cefixime, the tablet weight being not greater than 650 mg. 9. A tablet as claimed in claim 1, which contains 300-mg potency of cefdinir, the tablet weight being not greater than 450 mg. 10. A method of producing β-lactam antibiotic-containing tablets which comprises admixing a synthetic sweetener and/or a granulated synthetic sweetener, optionally together with one or more other additives, with a granulation product prepared from the β-lactam antibiotic, disintegrator and binder specified in claim 1, optionally together with one or more excipients, by using ethanol, isopropyl alcohol or an aqueous solution of ethanol or isopropyl alcohol, and then tableting the resulting mixture.
A fungal effector that is toxic to plant cells was identified in Verticillium dahliae. The effector contains a non-canonical Common in several Fungal Extracellular Membrane proteins (CFEM) domain, a tandem repeat region consisting of four 14-amino acid repeats rich in proline, and a C-terminal region, thus is designated V. dahliae tetrapeptide repeat protein (VdTRP). The membrane targeting of VdTRP is vital for its cell toxicity. CFEM mediates the membrane targeting and the tandem repeat region exerts the toxic function upon cell membrane. The chitinase-like 1 (CTL1), an essential apoplastic protein of cotton, can redirect VdTRP from cell membrane to apoplast. Transgenic cotton overexpressing CTL1 greatly enhances cotton resistance to V. dahliae without affecting cotton growth and development, implicating its potential application in breeding cotton with high wilt resistance. Our data demonstrates that genetic manipulation of effector target constitutes potential strategy for improving crop resistance to fungal pathogens.
In the era of precision medicine with increasing amounts of sequenced cancer and non-cancer genomes of different ancestries, we here enumerate the resulting polygenic disease entities. Based on the cell number status, we first identified six fundamental types of polygenic illnesses, five of which are non-cancerous. Like complex, non-tumor disorders, neoplasms normally carry alterations in multiple genes, including in 'Drivers' and 'Passengers'. However, tumors also lack certain genetic alterations/epigenetic changes, recently named 'Goners', which are toxic for the neoplasm and potentially constitute therapeutic targets. Drivers are considered essential for malignant transformation, whereas environmental influences vary considerably among both types of polygenic diseases. For each form, hyper-rare disorders, defined as affecting <1/108 individuals, likely represent the largest number of disease entities. Loss of redundant tumor-suppressor genes exemplifies such a profoundly rare mutational event. For non-tumor, polygenic diseases, pathway-centered taxonomies seem preferable. This classification is not readily feasible in cancer, but the inclusion of Drivers and possibly also of epigenetic changes to the existing nomenclature might serve as initial steps in this direction. Based on the detailed genetic alterations, the number of polygenic diseases is essentially countless, but different forms of nosologies may be used to restrict the number.
BACKGROUND: Previous studies have reported inconsistent results regarding the advantages or disadvantages of spironolactone use in patients undergoing hemodialysis (HD). This study aimed to evaluate survival according to the use of spironolactone in a large sample of patients undergoing maintenance HD.
METHODS: This retrospective study used laboratory and clinical data from the national HD Quality Assessment Program and claims data. The participants of the quality assessment program were patients who had been undergoing maintenance HD for ≥ 3 months, patients undergoing HD at least twice a week. Patients with no spironolactone prescription during the assessment periods were designated as the control group. Patients with one or more prescriptions of spironolactone during the assessment periods were assigned to the SPR group.
RESULTS: The number of patients in the control and SPR groups were 54,588 and 315, respectively. The 5-year survival rates were 69.1% and 59.1% in the control and SPR groups, respectively (P < 0.001). Cox regression analyses showed that the hazard ratio in the SPR group was 1.34 (P < 0.001) in univariate analysis and 1.13 (P = 0.249) in multivariable analysis. Univariate Cox-regression analysis showed a better patient survival rate in the control group than in the SPR group; however, multivariable analyses showed similar patient survival rates between the two groups.
CONCLUSION: This study showed no difference in survival between patients undergoing HD with and without spironolactone use.
We will recruit 12 Hispanic prepubertal children with CF (ages 7-12, Tanner I) and 12 Hispanic adolescents (ages 15-17, Tanner 3 or 4) from the CF Centers at University of Texas Southwestern and Baylor College of Medicine in Houston. Information obtained from these subjects will be compared to 12 prepubertal and 12 adolescent Caucasian children with CF recruited from the same CF centers. We will categorize the subjects according to glucose tolerance (OGTT), as well as insulin secretion and insulin sensitivity using the IVGTT and the Minimal Model, as modified for children. We will also compare the historical information of socio-economic status and family history. Clinical status will be characterized by measuring pulmonary function and modified NIH scores, in addition to measuring levels of circulating cytokines. Gluconeogenesis (GNG) will be quantified by measuring the incorporation 2H into the 2nd, 5th and 6th carbons of glucose. Whole body protein turnover (WBPT) will be measured using \[1-13C\]leucine. Nutritional status will be determined by three-day food journals, and intake will be compared to energy needs, utilizing indirect calorimetry to measure resting energy expenditure. Subjects will be recruited from the CF centers at the University of Texas- Southwestern and the South Central CF Consortium.
Inflammatory cytokines released by synovium after trauma disturb the gene regulatory network and have been implicated in the pathophysiology of osteoarthritis. A mechanistic understanding of how aging perturbs this process can help identify novel interventions. Here, we introduced network paradigms to simulate cytokine-mediated pathological communication between the synovium and cartilage. Cartilage-specific network analysis of injured young and aged murine knees revealed aberrant matrix remodeling as a transcriptomic response unique to aged knees displaying accelerated cartilage degradation. Next, network-based cytokine inference with pharmacological manipulation uncovered IL6 family member, Oncostatin M (OSM), as a driver of the aberrant matrix remodeling. By implementing a phenotypic drug discovery approach, we identified that the activation of OSM recapitulated an "inflammatory" phenotype of knee osteoarthritis and highlighted high-value targets for drug development and repurposing. These findings offer translational opportunities targeting the inflammation-driven osteoarthritis phenotype.
NEW MATERIAL:The compound of formulaI(R<1> is H or lower alkyl; R<2> is group of formula II or formula III), its cyclized lactone, and its pharmacologically permissible salt. EXAMPLE:3-Hydroxy-MB-530B carboxylic acid methyl ester. USE:A remedy for hyperlipemia and a preventive for arteriosclerosis. The compound of formulaIinhibits the synthesis of cholesterol. PROCESS:The compound of formulaIcan be prepared by culturing microorganisms belonging to Syncephalosporum genus, Mucor genus, Rhizopus genus, etc. in a medium containing an MB-530B compound such as MB-530B lactone, MB- 530B carboxylic acid, its pharmacologically permissible salt, MB-530B carboxylic acid alkyl ester, etc., or by contacting an MB-530B compound with the enzyme solution extracted from the above microorganisms.
OBJECTIVE: To construct a nomogram for predicting the responsiveness of cardiac resynchronization therapy (CRT) in patients with chronic heart failure and verify its predictive efficacy.
METHOD: A retrospective study was conducted including 109 patients with chronic heart failure who successfully received CRT from January 2018 to December 2022. According to patients after six months of the CRT preoperative improving acuity in the left ventricular ejection fraction is 5% or at least improve grade 1 NYHA heart function classification, divided into responsive group and non-responsive group. Clinical data of patients were collected, and LASSO regression analysis and multivariate logistic regression analysis were used to explore relative factors. A nomogram was constructed, and the predictive performance of the nomogram was evaluated using the calibration curve and decision curve analysis (DCA).
RESULTS: Among the 109 patients, 61 were assigned to the CRT-responsive group, while 48 were assigned to the non-responsive group. LASSO regression analysis showed that left ventricular end-systolic volume, diffuse fibrosis, and left bundle branch block (LBBB) were independent factors for CRT responsiveness in patients with heart failure (P < 0.05). Based on the above three predictive factors, a nomogram was constructed. The ROC curve analysis showed that the area under the curve (AUC) was 0.865 (95% CI 0.794-0.935). The calibration curve analysis showed that the predicted probability of the nomogram is consistent with the actual occurrence rate. DCA showed that the line graph model has an excellent clinical net benefit rate.
CONCLUSION: The nomogram constructed based on clinical features, laboratory, and imaging examinations in this study has high discrimination and calibration in predicting CRT responsiveness in patients with chronic heart failure.
Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 \& 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 \& 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age \& 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
PURPOSE: Appropriate surveillance of patients with melanoma treated with curative intent is vital to improve patient outcomes. A systematic review was conducted to capture locoregional recurrence and metastatic disease, and to evaluate the effectiveness of various surveillance strategies.
METHODS: MEDLINE, EMBASE, PubMed, Cochrane Database of Systematic Reviews, and National Cancer Institute Clinical Trials Database were searched. Randomized controlled trials (RCTs) and comparative studies reporting at least one patient-related outcome were included. Exclusion criteria included: published in non-English or recruited >20 % or an uncertain percentage of non-target patients without conducting a subgroup analysis for the target patients. This review was registered at PROSPERO (CRD42021246482).
RESULTS: Among 17,978 publications from the literature search, one RCT and five non-randomized comparative studies were included and comprised 4016 patients. The aggregate evidence certainty was low for the RCT and very low for the comparative studies, as assessed by the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. For patients with stage IA-IIC melanoma, a reduced follow-up schedule with clinical follow-up strategies alone may be safe and cost-effective. For stage IIC-IIIC patients, at least two serial PET/CT or whole-body CT and brain MRI imaging within a median follow-up of 31.2 months may detect 50 % of recurrences that lead to additional management, such as surgery. PET/CT may have a higher positive predictive value and lower false positive rate compared with CT alone in detecting recurrence in stage I-III patients.
CONCLUSION: Surveillance protocols should be based on individual risk of recurrence and established best practices when formulating follow-up strategies, as suggested by the studies reviewed. Future high-quality studies are needed to clarify the frequency of imaging follow-up strategies, especially in patients with high-risk stage II melanoma.
<P>PROBLEM TO BE SOLVED: To provide a whey protein-containing nutrient composition withstanding a homogenizing treatment or a heat sterilizing treatment in a production process, ensuring emulsion stability even after preparation, having homogeneous contents ingredient and a good flavor and ingestible during feeding to the aged, patients etc., requiring the feeding by combining specific emulsifying agents and carrying out emulsification even when a whey protein is formulated.  <P>SOLUTION: The whey protein-containing nutrient composition comprises the whey protein. The whey protein-containing nutrient composition comprises following (A) and (B) as the emulsifying agents, uses the emulsifying agent (B) in an amount of 0.5-3 pts.wt. based on 1 pt.wt. of the (A) and is liquid after heat sterilization. (A) one or more organic acid monoglycerides selected from among the group consisting of succinic acid glycerol monostearate, lactic acid glycerol monostearate, and diacetyltartaric acid glycerol monostearate, and (B) a polyglycerol fatty acid ester having 12-14 value of HLB and ≤60°C melting point of fatty acids composing the emulsifying agent.  <P>COPYRIGHT: (C)2009,JPO&INPIT